Abstract
Great strides have been made in recent years on the development of tau immunotherapies for Alzheimer’s disease and other tauopathies. Multiple animal studies by several groups have shown efficacy of various active and passive approaches in reducing pathological tau proteins. Clinical trials are clearly warranted and a few have already been initiated. However, much remains to be clarified regarding the mechanisms of action and how efficacy can be improved and potential toxicity minimized. These are exciting times for the field and will hopefully lead to an effective therapy in the near future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of A beta(42) immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634):216–223
Aisen PS, Vellas B (2013) Passive immunotherapy for Alzheimer’s disease: what have we learned, and where are we headed? J Nutr Health Aging 17(1):49–50
Fagan T (2014) Crenezumab disappoints - Phase 2 - Researchers remain hopeful. http://www.alzforum. org/news/conference-coverage/crenezumab-disappoints-phase-2-researchers-remain-hopeful. Accessed 13 Aug 2014
Strobel G (2015) Aducanumab, solanezumab, gantenerumab data lift crenezumab, as well. http://www.alzforum.org/news/conference-coverage/aducanumab-solanezumab-gantenerumab-data-lift-crenezumab-well. Accessed 21 Aug 2015
Wilcock GK, Esiri MM (1982) Plaques, tangles and dementia: a quantitative study. J Neurol Sci 56(2-3):343–356
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42(3 Pt 1):631–639
Strobel G (2014) NIH director announces $100M prevention trial of Genentech antibody. http://www. alzforum.org/news/conference-coverage/nih-director-announces-100m-prevention-trial-genentech-antibody. Accessed 13 Aug 2014
Sigurdsson EM. Immune therapy for AD plaques and tangles. [Project period begin date 09/30/2001]. NIH, 1R01AG020197
Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34):9115–9129
Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30(49):16559–16566
Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118(4):658–667
Krishnamurthy PK, Deng Y, Sigurdsson EM (2011) Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry 2:59
Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer’s disease and related tauopathies. Curr Alzheimer Res 6(5):446–450
Congdon EE, Gu J, Sait HB, Sigurdsson EM (2013) Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem 288(49):35452–35465
Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284(19):12845–12852
Clavaguera F, Bolmont T, Crowther RA et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11(7):909–913
Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF (2010) Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis 19(2):647–664
Liu L, Drouet V, Wu JW et al (2012) Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7(2):e31302
Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular propagation of tau aggregation by fibrillar species. J Biol Chem 287(23):19440–19451
Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM (2012) Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of tau protein in aggresomes. J Biol Chem 287(24):20522–20533
Wu JW, Herman M, Liu L et al (2013) Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288(3):1856–1870
Masliah E, Rockenstein E, Adame A et al (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 46(6):857–868
Tampellini D, Magrane J, Takahashi RH et al (2007) Internalized antibodies to the A beta domain of APP reduce neuronal A beta and protect against synaptic alterations. J Biol Chem 282(26):18895–18906
Masliah E, Rockenstein E, Mante M et al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6(4), e19338
Urushitani M, Ezzi SA, Julien JP (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 104(7):2495–2500
Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224(2):472–485
Chai X, Wu S, Murray TK et al (2011) Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem 286(39):34457–34467
Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6(12):e26860
Troquier L, Caillierez M, Burnouf S et al (2012) Targeting phospho-Ser422 by active tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9(4):397–405
d’Abramo C, Acker CM, Jimenez HT, Davies P (2013) Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE 8(4):e62402
Theunis C, Crespo-Biel N, Gafner V et al (2013) Efficacy and safety of a liposome-based vaccine against protein tau, assessed in Tau.P301L mice that model tauopathy. PLoS One 8(8):e72301
Yanamandra K, Kfoury N, Jiang H et al (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80(2):402–414
Gu J, Congdon EE, Sigurdsson EM (2013) Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. J Biol Chem 288(46):33081–33095
Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Kayed R (2014) Specific targeting of tau oligomers in hTau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis 40:S97–S111
Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ et al (2014) Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34(12):4260–4272
Walls KC, Ager RR, Vasilevko V, Cheng D, Medeiros R, LaFerla FM (2014) p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett 575:96–100
Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F (2014) Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain 137(Pt 10):2834–2846
Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther 6(4):44
Selenica ML, Davtyan H, Housley SB et al (2014) Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation 11:152
Bright J, Hussain S, Dang V et al (2015) Human secreted tau increases amyloid-beta production. Neurobiol Aging 36(2):693–709
Umeda T, Eguchi H, Kunori Y et al (2015) Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol 2(3):241–255
Sankaranarayanan S, Barten DM, Vana L et al (2015) Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10(5):e0125614
Kondo A, Shahpasand K, Mannix R et al (2015) Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature 523(7561):431–436
Yanamandra K, Jiang H, Mahan TE et al (2015) Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2(3):278–288
Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI (2015) Distinct therapeutic mechanisms of tau antibodies: promoting microglial clearance vs. blocking neuronal uptake. J Biol Chem 290(35):21652–62
d’Abramo C, Acker CM, Jimenez H, Davies P (2015) Passive immunization in JNPL3 transgenic mice using an array of phospho-tau specific antibodies. PLoS One 10(8):e0135774
Ittner A, Bertz J, Suh LS, Stevens CH, Gotz J, Ittner LM (2015) Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem 132(1):135–145
Bumbaca D, Boswell CA, Fielder PJ, Khawli LA (2012) Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 14(3):554–558
Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J Alzheimers Dis 15:157–168
Pfeifer M, Boncristiano S, Bondolfi L et al (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298(5597):1379
Morgan D (2009) The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets 8(1):7–15
Chai X, Dage JL, Citron M (2012) Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis 48(3):356–366
Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ (2012) A human stem cell model of early Alzheimer’s disease pathology in Down syndrome. Sci Transl Med 4(124):124ra29
Saman S, Kim W, Raya M et al (2012) Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287(6):3842–3849
Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J (2012) Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett 586(1):47–54
Yamada K, Cirrito JR, Stewart FR et al (2011) In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31(37):13110–13117
Plouffe V, Mohamed NV, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc N (2012) Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS One 7(5):e36873
Karch CM, Jeng AT, Goate AM (2012) Extracellular tau levels are influenced by variability in tau that is associated with tauopathies. J Biol Chem 287(51):42751–42762
Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14(4):389–394
Medina M, Avila J (2014) The role of extracellular tau in the spreading of neurofibrillary pathology. Front Cell Neurosci 8:113
Rosenmann H, Grigoriadis N, Karussis D et al (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63(10):1459–1467
Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A et al (2013) Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 248:451–456
Mably AJ, Kanmert D, Mc Donald JM et al (2015) Tau immunization: a cautionary tale? Neurobiol Aging 36(3):1316–1332
Harada A, Oguchi K, Okabe S et al (1994) Altered microtubule organization in small-caliber axons of mice lacking tau-protein. Nature 369(6480):488–491
Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114(6):1179–1187
Tucker KL, Meyer M, Barde YA (2001) Neurotrophins are required for nerve growth during development. Nat Neurosci 4(1):29–37
Fujio K, Sato M, Uemura T, Sato T, Sato-Harada R, Harada A (2007) 14-3-3 proteins and protein phosphatases are not reduced in tau-deficient mice. Neuroreport 18(10):1049–1052
Ikegami S, Harada A, Hirokawa N (2000) Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett 279(3):129–132
Lei P, Ayton S, Finkelstein DI et al (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18(2):291–295
Ke YD, Suchowerska AK, van der Hoven J et al (2012) Lessons from tau-deficient mice. Int J Alzheimers Dis 2012:873270
Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99(9):6364–6369
Roberson ED, Scearce-Levie K, Palop JJ et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316(5825):750–754
Ittner LM, Ke YD, Delerue F et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142(3):387–397
Congdon EE, Krishnaswamy S, Sigurdsson EM (2014) Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis 40:S113–S121
Krishnaswamy S, Lin Y, Rajamohamedsait WJ, Rajamohamedsait HB, Krishnamurthy P, Sigurdsson EM (2014) Antibody-derived in vivo imaging of tau pathology. J Neurosci 34(50):16835–16850
Axon Neuroscience SE (2015) NCT01850238: safety study of AADvac1, a tau peptide-KLH-conjugate active vaccine to treat Alzheimer’s disease. ClinicalTrials.gov
Bristol-Meyers Squibb (2015) NCT02294851: a randomized, double-blind, placebo-controlled, single ascending dose study of intravenously administered BMS-986168 in healthy subjects. ClinicalTrials.gov
Bristol-Meyers Squibb (2015) NCT02460094: Multiple ascending dose study of intravenously administered BMS-986168 in patients with progressive supranuclear palsy (CN002-003). ClinicalTrials.gov
Hoffmann-La-Roche (2015) NCT02281786: a study of RO6926496 in healthy volunteers. ClinicalTrials.gov
C2N Diagnostics - Abbvie (2015) NCT02494024: safety, tolerability and pharmacokinetics of C2N-8E12 in subjects with progressive supranuclear palsy. ClinicalTrials.gov
Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer’s disease. Trends Mol Med 21(6):394–402
Acknowledgements
E.M.S. is supported by NIH grants NS077239, AG032611, and AG020197. He is an inventor on patents on tau immunotherapy and related diagnostics that are assigned to New York University. This technology is licensed to and is being co-developed with H. Lundbeck A/S.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Sigurdsson, E.M. (2016). Tau Immunotherapy. In: Ingelsson, M., Lannfelt, L. (eds) Immunotherapy and Biomarkers in Neurodegenerative Disorders. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3560-4_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3560-4_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3558-1
Online ISBN: 978-1-4939-3560-4
eBook Packages: Springer Protocols